Literature DB >> 3519788

The relation between production of cytotoxin and clinical features in shigellosis.

D Prado, T G Cleary, L K Pickering, C D Ericsson, A V Bartlett, H L DuPont, P C Johnson.   

Abstract

The relation between in vitro production of HeLa cell cytotoxin by strains of Shigella and clinical symptomatology was determined for 35 travelers from the United States who developed shigellosis in Guadalajara, Mexico. There were 25 patients with Shigella sonnei, eight with Shigella flexneri, one with Shigella boydii, and one with Shigella dysenteriae. These strains were evaluated for in vitro production of cytotoxin. The amount of cytotoxin did not correlate with the number of stools passed, the severity of abdominal pain, or the presence of nausea or vomiting. However, patients with strains of Shigella that produced more cytotoxic activity were more likely to have fever (P less than .02) and occult blood in their stools (P less than .004). The cytotoxicity produced by 30 (86%) strains could not be neutralized with rabbit antiserum to purified, formaldehyde-treated Shiga toxin from S. dysenteriae type 1 strain 60 R; the cytotoxicity of five (14%) of the strains was partially neutralized. When only nonneutralizable cytotoxin was considered, the presence of fecal leukocytes (P less than .04), as well as of occult blood (P less than .002) and fever (P less than .02), correlated with the amount of cytotoxin. The amount of nonneutralizable cytotoxin produced by shigella strains was related to the clinical findings. This cytotoxic activity was infrequently attributable to "Shiga toxin".

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519788     DOI: 10.1093/infdis/154.1.149

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Genetic basis of virulence in Shigella species.

Authors:  T L Hale
Journal:  Microbiol Rev       Date:  1991-06

2.  Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1.

Authors:  A Fontaine; J Arondel; P J Sansonetti
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

Review 3.  Shiga and Shiga-like toxins.

Authors:  A D O'Brien; R K Holmes
Journal:  Microbiol Rev       Date:  1987-06

4.  Molecular evolution of large virulence plasmid in Shigella clones and enteroinvasive Escherichia coli.

Authors:  R Lan; B Lumb; D Ryan; P R Reeves
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Authors:  Leticia H Nolasco; Nancy A Turner; Aubrey Bernardo; Zhenyin Tao; Thomas G Cleary; Jing-Fei Dong; Joel L Moake
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

6.  Enterotoxin and cytotoxin production by enteroinvasive Escherichia coli.

Authors:  A Fasano; B A Kay; R G Russell; D R Maneval; M M Levin
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

7.  Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor.

Authors:  S Ashkenazi; T G Cleary
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

8.  Quantitative analysis and partial characterization of cytotoxin production by Salmonella strains.

Authors:  S Ashkenazi; T G Cleary; B E Murray; A Wanger; L K Pickering
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome.

Authors:  Y Harel; M Silva; B Giroir; A Weinberg; T B Cleary; B Beutler
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Human milk secretory antibodies against attaching and effacing Escherichia coli antigens.

Authors:  Marita Noguera-Obenza; Theresa J Ochoa; Henry F Gomez; M Lourdes Guerrero; Irene Herrera-Insua; Ardythe L Morrow; Guillermo Ruiz-Palacios; Larry K Pickering; Carlos A Guzman; Thomas G Cleary
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.